E-liquid Coolants for Nicotine Addiction

Overseen By Wei Li, PhD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Yale University

Disqualifiers: Medical condition, Hypersensitivity, Pregnant, Asthma, Allergy, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 3

Duration: 3 sessions

66 Participants Needed

Trial Summary

What is the purpose of this trial?

This study is an examination of the influence of cooling components of WS-3, WS-23, and menthol on the appeal and addiction potential of nicotine-containing e-liquids among adults.

Research Team

Suchitra Krishnan-Sarin, PhD

Principal Investigator

Yale University

Eligibility Criteria

This trial is for adults who can read and write, currently use e-cigarettes to some extent, and are willing to refrain from using tobacco or nicotine for at least 2 hours before the study sessions.

Inclusion Criteria

Able to read and write

Some current e-cigarette use

Willing to abstain from tobacco/nicotine use 2 hrs prior to sessions

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants attend 3 laboratory sessions to evaluate the appeal and addiction potential of e-cigarettes with different cooling components

3 sessions

3 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• E-liquid coolant

Trial Overview The study tests how different cooling agents (WS-3, WS-23) and levels of menthol in e-liquids affect their appeal and potential to increase addiction to nicotine among adult users.

Participant Groups

Group I: Non-menthol, nicotine 59mg/ml (5) Experimental Treatment 1 Intervention

Flavor without menthol with 59mg/ml nicotine

Group II: Non-menthol, nicotine 59mg/ml (4) Experimental Treatment 1 Intervention

Flavor without menthol with 59mg/ml nicotine

Group III: Non-menthol, nicotine 59mg/ml (3) Experimental Treatment 1 Intervention

Flavor without menthol with 59mg/ml nicotine

Group IV: Non-menthol, nicotine 59mg/ml (2) Experimental Treatment 1 Intervention

Flavor without menthol with 59mg/ml nicotine

Group V: Non-menthol, nicotine 59mg/ml (1) Experimental Treatment 1 Intervention

Flavor without menthol with 59mg/ml nicotine

Group VI: Low menthol, nicotine 59mg/ml (5) Experimental Treatment 1 Intervention

Flavor low menthol concentration with 59mg/ml nicotine

Group VII: Low menthol, nicotine 59mg/ml (4) Experimental Treatment 1 Intervention

Flavor low menthol concentration with 59mg/ml nicotine

Group VIII: Low menthol, nicotine 59mg/ml (3) Experimental Treatment 1 Intervention

Flavor with low menthol concentration with 59mg/ml nicotine

Group IX: Low menthol, nicotine 59mg/ml (2) Experimental Treatment 1 Intervention

Flavor with low menthol concentration with 59mg/ml nicotine

Group X: Low menthol, nicotine 59mg/ml (1) Experimental Treatment 1 Intervention

Flavor with low menthol concentration with 59mg/ml nicotine

Group XI: High menthol, nicotine 59mg/ml (5) Experimental Treatment 1 Intervention

Flavor high menthol concentration with 59mg/ml nicotine

Group XII: High menthol, nicotine 59mg/ml (4) Experimental Treatment 1 Intervention

Flavor high menthol concentration with 59mg/ml nicotine

Group XIII: High menthol, nicotine 59mg/ml (3) Experimental Treatment 1 Intervention

Flavor with high menthol concentration with 59mg/ml nicotine

Group XIV: High menthol, nicotine 59mg/ml (2) Experimental Treatment 1 Intervention

Flavor with high menthol concentration with 59mg/ml nicotine

Group XV: High menthol, nicotine 59mg/ml (1) Experimental Treatment 1 Intervention

Flavor with high menthol concentration with 59mg/ml nicotine

Who Is Running the Clinical Trial?

Yale University

Lead Sponsor

Trials

1,963

Recruited

3,046,000+

National Institute on Drug Abuse (NIDA)

Collaborator

Trials

2,658

Recruited

3,409,000+